Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management

J Urol. 2021 Jan;205(1):137-144. doi: 10.1097/JU.0000000000001337. Epub 2020 Aug 28.

Abstract

Purpose: Current serum tumor markers for testicular germ cell tumor are limited by low sensitivity. Growing evidence supports the use of circulating miR-371a-3p as a superior marker for malignant (viable) germ cell tumor management. We evaluated the real-world application of serum miR-371a-3p levels in detecting viable germ cell tumor among patients undergoing partial or radical orchiectomy.

Materials and methods: Serum samples were collected from 69 consecutive patients before orchiectomy. Performance characteristics of serum miR-371a-3p were compared with conventional serum tumor markers (⍺-fetoprotein/β-human chorionic gonadotropin/lactate dehydrogenase) between patients with viable germ cell tumor and those without viable germ cell tumor on orchiectomy pathology. Relative miR-371a-3p levels were correlated with clinical course. The Kruskal-Wallis test and linear and ordinal regression models were used for analysis.

Results: For detecting viable germ cell tumor, combined conventional serum tumor markers had a specificity of 100%, sensitivity of 58% and AUC of 0.79. The miR-371a-3p test showed a specificity of 100%, sensitivity of 93% and AUC of 0.978. Median relative expression of miR-371a-3p in viable germ cell tumor cases was more than 6,800-fold higher than in those lacking viable germ cell tumor. miR-371a-3p levels correlated with composite stage (p=0.006) and, among composite stage I cases, independently associated with embryonal carcinoma percentage (p=0.0012) and tumor diameter (p <0.0001). Six patients underwent orchiectomy after chemotherapy and were correctly predicted to have presence or absence of viable germ cell tumor by the miR-371a-3p test.

Conclusions: If validated, the miR-371a-3p test can be used in conjunction with conventional serum tumor markers to aid clinical decision making. A positive miR-371a-3p test in patients after preoperative chemotherapy or with solitary testes could potentially guide subsequent orchiectomy or observation.

Keywords: biomarkers; germ cell and embryonal; microRNAs; neoplasms; testicular neoplasms.

MeSH terms

  • Adult
  • Biomarkers, Tumor / blood*
  • Case-Control Studies
  • Chemotherapy, Adjuvant
  • Circulating MicroRNA / blood*
  • Clinical Decision-Making / methods
  • Feasibility Studies
  • Humans
  • Male
  • MicroRNAs / blood*
  • Middle Aged
  • Neoadjuvant Therapy / methods
  • Neoplasm Staging
  • Neoplasms, Germ Cell and Embryonal / blood
  • Neoplasms, Germ Cell and Embryonal / diagnosis*
  • Neoplasms, Germ Cell and Embryonal / pathology
  • Neoplasms, Germ Cell and Embryonal / therapy
  • Orchiectomy*
  • Preoperative Period
  • Testicular Neoplasms / blood
  • Testicular Neoplasms / diagnosis*
  • Testicular Neoplasms / pathology
  • Testicular Neoplasms / therapy
  • Testis / pathology
  • Testis / surgery
  • Watchful Waiting

Substances

  • Biomarkers, Tumor
  • Circulating MicroRNA
  • MIRN371 microRNA, human
  • MicroRNAs

Supplementary concepts

  • Testicular Germ Cell Tumor